CR6513A - Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas - Google Patents
Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticasInfo
- Publication number
- CR6513A CR6513A CR6513A CR6513A CR6513A CR 6513 A CR6513 A CR 6513A CR 6513 A CR6513 A CR 6513A CR 6513 A CR6513 A CR 6513A CR 6513 A CR6513 A CR 6513A
- Authority
- CR
- Costa Rica
- Prior art keywords
- polymorphes
- oct
- citrate
- crystalline
- pharmeceutic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
- AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DOS FORMAS POLIMORFICAS CRISTALINAS DE CITRATO DE (2-BENZIHIDRIL-1-AZO-BICICLO (2.2.2) OCT-3-IL)- (5-ISOPROPIL-2-METOXIBENCIL) AMINA MONOHIDRATO (LOS MONOHIDRATOS) SON LA FORMA A Y LA FORMA B. LA COMPOSICION FARMACEUTICA QUE CONTIENE AL MENOS UNO DE ESTOS POLIMORFOS TIENE UNA ESTABILIDAD VENTAJOSA PARA LA FORMULACION PARA EL TRATAMIENTO DE EMESIS AYUDA EN PACIENETES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES CONVENCIONALMENTE ORAL, MEDIANTE PREFERIBLEMENTE COMPROIMIDOS O CAPSULAS E INTRAVENOSA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699599P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR6513A true CR6513A (es) | 2003-11-25 |
Family
ID=22475353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR6513A CR6513A (es) | 1999-06-01 | 2001-11-27 | Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6387925B1 (es) |
| EP (1) | EP1181289A1 (es) |
| JP (1) | JP2003501353A (es) |
| KR (1) | KR20020005055A (es) |
| CN (1) | CN1353712A (es) |
| AP (1) | AP2001002350A0 (es) |
| AR (1) | AR029753A1 (es) |
| AU (1) | AU767331B2 (es) |
| BG (1) | BG106139A (es) |
| BR (1) | BR0011125A (es) |
| CA (1) | CA2372236A1 (es) |
| CO (1) | CO5170468A1 (es) |
| CR (1) | CR6513A (es) |
| CZ (1) | CZ20014270A3 (es) |
| DZ (1) | DZ3051A1 (es) |
| EA (1) | EA004206B1 (es) |
| EE (1) | EE200100655A (es) |
| GT (1) | GT200000086A (es) |
| HK (1) | HK1046407A1 (es) |
| HN (1) | HN2000000076A (es) |
| HR (1) | HRP20010884A2 (es) |
| HU (1) | HUP0201798A3 (es) |
| IL (1) | IL145952A0 (es) |
| IS (1) | IS6129A (es) |
| MX (1) | MXPA01012328A (es) |
| NO (1) | NO20015845L (es) |
| NZ (1) | NZ514762A (es) |
| OA (1) | OA11955A (es) |
| PA (1) | PA8496001A1 (es) |
| PE (1) | PE20010155A1 (es) |
| PL (1) | PL352715A1 (es) |
| SK (1) | SK17342001A3 (es) |
| SV (1) | SV2002000092A (es) |
| TN (1) | TNSN00119A1 (es) |
| TR (1) | TR200103472T2 (es) |
| UY (1) | UY26177A1 (es) |
| WO (1) | WO2000073303A1 (es) |
| ZA (1) | ZA200109839B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031191A1 (en) * | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Azabicyclic spiroether derivatives as receptor antagonists |
| EP1790635A3 (en) * | 2003-06-18 | 2007-06-13 | Teva Pharmaceutical Industries, Inc. | Processes for preparing amorphous fluvastatin sodium |
| US7371906B2 (en) | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| DK0587723T3 (da) * | 1991-05-31 | 1996-04-01 | Pfizer | Quinuclidinderivater |
| DE69307340T2 (de) * | 1992-11-12 | 1997-04-24 | Pfizer | Chinuclidin derivat als substanz p antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
-
2000
- 2000-05-12 US US09/887,682 patent/US6387925B1/en not_active Expired - Fee Related
- 2000-05-17 HU HU0201798A patent/HUP0201798A3/hu unknown
- 2000-05-17 CZ CZ20014270A patent/CZ20014270A3/cs unknown
- 2000-05-17 IL IL14595200A patent/IL145952A0/xx unknown
- 2000-05-17 EA EA200100982A patent/EA004206B1/ru not_active IP Right Cessation
- 2000-05-17 TR TR2001/03472T patent/TR200103472T2/xx unknown
- 2000-05-17 BR BR0011125-2A patent/BR0011125A/pt not_active IP Right Cessation
- 2000-05-17 EP EP00925526A patent/EP1181289A1/en not_active Withdrawn
- 2000-05-17 AP APAP/P/2001/002350A patent/AP2001002350A0/en unknown
- 2000-05-17 JP JP2001500628A patent/JP2003501353A/ja active Pending
- 2000-05-17 HN HN2000000076A patent/HN2000000076A/es unknown
- 2000-05-17 CA CA002372236A patent/CA2372236A1/en not_active Abandoned
- 2000-05-17 WO PCT/IB2000/000663 patent/WO2000073303A1/en not_active Application Discontinuation
- 2000-05-17 AU AU44246/00A patent/AU767331B2/en not_active Ceased
- 2000-05-17 MX MXPA01012328A patent/MXPA01012328A/es not_active Application Discontinuation
- 2000-05-17 KR KR1020017015324A patent/KR20020005055A/ko not_active Application Discontinuation
- 2000-05-17 EE EEP200100655A patent/EE200100655A/xx unknown
- 2000-05-17 CN CN00808340A patent/CN1353712A/zh active Pending
- 2000-05-17 SK SK1734-2001A patent/SK17342001A3/sk unknown
- 2000-05-17 NZ NZ514762A patent/NZ514762A/xx unknown
- 2000-05-17 OA OA1200100317A patent/OA11955A/en unknown
- 2000-05-17 PL PL00352715A patent/PL352715A1/xx not_active Application Discontinuation
- 2000-05-19 PA PA20008496001A patent/PA8496001A1/es unknown
- 2000-05-26 CO CO00039192A patent/CO5170468A1/es not_active Application Discontinuation
- 2000-05-29 UY UY26177A patent/UY26177A1/es not_active Application Discontinuation
- 2000-05-30 GT GT200000086A patent/GT200000086A/es unknown
- 2000-05-30 PE PE2000000517A patent/PE20010155A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102664A patent/AR029753A1/es unknown
- 2000-05-31 TN TNTNSN00119A patent/TNSN00119A1/fr unknown
- 2000-05-31 SV SV2000000092A patent/SV2002000092A/es unknown
- 2000-05-31 DZ DZ000102A patent/DZ3051A1/xx active
-
2001
- 2001-10-26 IS IS6129A patent/IS6129A/is unknown
- 2001-11-23 BG BG106139A patent/BG106139A/bg unknown
- 2001-11-27 CR CR6513A patent/CR6513A/es not_active Application Discontinuation
- 2001-11-27 HR HR20010884A patent/HRP20010884A2/hr not_active Application Discontinuation
- 2001-11-29 ZA ZA200109839A patent/ZA200109839B/xx unknown
- 2001-11-30 NO NO20015845A patent/NO20015845L/no not_active Application Discontinuation
-
2002
- 2002-10-30 HK HK02107840.5A patent/HK1046407A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| AR034691A1 (es) | Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende | |
| SV1998000029A (es) | Compuestos de pirazina ref. pg3186 | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
| AR066982A2 (es) | Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| EE04799B1 (et) | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
| CL2009001279A1 (es) | Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03). | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| ES2065701T3 (es) | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. | |
| AR018197A1 (es) | Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
| DK1121127T3 (da) | Orale farmaceutiske sammensætninger, som indeholder buprenorphin | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| ECSP034766A (es) | Una combinacion que comprende combretastatina y agentes anticancerigenos | |
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| HUP0200055A2 (hu) | 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények | |
| CR6513A (es) | Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas | |
| UY26211A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas | |
| BR0114395A (pt) | Composição farmacêutica para administração por suprimento via oral | |
| AR003434A1 (es) | Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas. | |
| ECSP003508A (es) | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas | |
| ECSP003510A (es) | Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |